Callan Capital LLC Has $622,000 Holdings in Sanofi (NASDAQ:SNY)

Callan Capital LLC cut its stake in Sanofi (NASDAQ:SNY) by 12.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 12,900 shares of the company’s stock after selling 1,813 shares during the period. Callan Capital LLC’s holdings in Sanofi were worth $622,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Abel Hall LLC increased its stake in shares of Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares during the last quarter. PDS Planning Inc increased its stake in shares of Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after acquiring an additional 200 shares during the last quarter. Financial Advocates Investment Management increased its stake in shares of Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after acquiring an additional 206 shares during the last quarter. Angeles Investment Advisors LLC increased its stake in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after acquiring an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after purchasing an additional 217 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SNY has been the subject of a number of research reports. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $54.46 on Friday. The stock has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The business has a 50 day simple moving average of $50.95 and a 200 day simple moving average of $52.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.